Showing 708 results
-
Media Release /
-
Media Release /Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple…
-
Media Release /
-
Media Release /If approved, Xolair self-administration would offer a more flexible option to help select patients manage their treatment needs Filing acceptance is based on the well-established efficacy and…
-
Media Release /
-
Media Release /Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis¹…
-
Media Release /Approximately 3 million people in the US suffer from HFpEF, a life-threatening condition associated with frequent heart failure hospitalizations and emergency room visits, for which no treatment…
-
Media Release /
-
Media Release /FDA approval for Cosentyx is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial spondyloarthritis…
-
Media Release /FDA granted an indication for active Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) and AOSD, a serious and rare inflammatory disorder with high unmet medical need1,2…
